Topical steroids and topical tacrolimus appear safe regarding the COVID-19 epidemic

Souaid, K.; Klejtman, T.; Kramkimel, N.; Isnard, C.; Dupin, Nicolas; Aractingi, S.

doi:10.1016/j.annder.2020.12.001

Cited by 7 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effect of dupilumab on the expression of ACE2 and other entry receptors for SARS-CoV-2 as well as the immune responses to SARS-CoV-2 infection needs to be further investigated. Other medications used for the treatment of AD, including topical steroids and calcineurin inhibitors, did not increase the severity of COVID-19 ( 115 ).…”

Section: Atopic Dermatitismentioning

confidence: 93%

The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19

Gao

Agache

Akdiş

et al. 2021

International Immunology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic causes an overwhelming number of hospitalization and deaths with a significant socioeconomic impact. The vast majority of studies indicate that asthma and allergic diseases do not represent a risk factor for COVID-19 susceptibility nor cause a more severe course of disease. This raises the opportunity to investigate the underlying mechanisms of the interaction between an allergic background and SARS-CoV-2 infection. The majority of patients with asthma, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, food and drug allergies exhibit an overexpression of type 2 immune and inflammatory pathways with the contribution of epithelial cells, innate lymphoid cells (ILC), dendritic cells, T cells, eosinophils, mast cells, basophils and the type 2 cytokines interleukin (IL)-4, IL-5, IL-9, IL-13, and IL-31. The potential impact of type 2 inflammation-related allergic diseases on susceptibility to COVID-19 and severity of its course have been reported. In this review, the prevalence of asthma and other common allergic diseases in COVID-19 patients is addressed. Moreover, the impact of allergic and non-allergic asthma with different severity and control status, currently available asthma treatments such as inhaled and oral corticosteroids, short- and long-acting β2 agonists, leukotriene receptor antagonists and biologicals on the outcome of COVID-19 patients is reviewed. In addition, possible protective mechanisms of asthma and type 2 inflammation on COVID-19 infection, such as the expression of SARS-CoV-2 entry receptors, antiviral activity of eosinophils, cross-reactive T cell epitopes are discussed. Potential interactions of other allergic diseases with COVID-19 are postulated, including recommendations for their management.

show abstract

Section: Atopic Dermatitismentioning

confidence: 93%

The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19

Gao

Agache

Akdiş

et al. 2021

International Immunology

View full text Add to dashboard Cite

show abstract

“…Neither hospitalization nor oxygen therapy was needed. No complications in these patients were observed [35].…”

Section: Discussionmentioning

confidence: 68%

The impact of limited access of photodynamic therapy during COVID-19 pandemic on patients with vulvar lichen sclerosus

Bizoń¹,

Ostrowska

Wieczorek

et al. 2023

Ginekol Pol

View full text Add to dashboard Cite

Objectives: Stressful situations have an impact on progression of lichen sclerosus. The aim of the study was to investigate fears and complaints of patients with vulvar lichen sclerosus and progression of disease at the beginning of the COVID-19 pandemic. Material and methods:The analysis was based on 103 women with mean age was 64.81 ± 11.36 years divided into two groups. The first one comprised of patients with stabilization of disease during the pandemic with mean age 66.02 ± 10.01 (32-87), while the second one with progression of vulvar symptoms with mean age 63.49 ± 12.66 (25-87).Results: Delay of diagnosis was reported to be a problem for respectively 25.93% of women from both groups. Fear about COVID-19 was described respectively by 57.4% and 55.1%. Stabilization of disease was more frequent in patients after photodynamic therapy before pandemic. Progression of vulvar symptoms and features were observed more in patients who did not conduct PDT previously. All patients from the second group who underwent photodynamic therapy reported disappointment because of no access for continuation of treatment. On the other hand, 81.4% (43 women) regret that have no chance for trying photodynamic therapy.Conclusions: Photodynamic therapy seems to be a method of treatment with longer survival without progression of lichen sclerosus in times of pandemics. There has been no investigation until now about concerns of patients with vulvar lichen sclerosus. Better understanding of problems connected with the pandemic can help medical personnel in taking care of patients with vulvar lichen sclerosus.

show abstract

“…Ces patients restent donc considérés comme à risque de COVID-19 sévère, ne serait-ce que du fait de leur pathologie auto-immune sous-jacente. En revanche, les dermocorticoïdes ne sont pas associés à un surrisque de forme sévère de COVID-19 [ 22 ].…”

Section: Traitements Systémiques Et Risque De Développer Une Forme Sévère De Covid-19unclassified

Traitements systémiques et risque infectieux dans le contexte de pandémie COVID-19

Villani

2021

Annales de Dermatologie et de Vénéréologie - FMC

View full text Add to dashboard Cite

Topical steroids and topical tacrolimus appear safe regarding the COVID-19 epidemic

Cited by 7 publications

References 4 publications

The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19

The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19

The impact of limited access of photodynamic therapy during COVID-19 pandemic on patients with vulvar lichen sclerosus

Traitements systémiques et risque infectieux dans le contexte de pandémie COVID-19

Contact Info

Product

Resources

About